

BioPune Series Public Health Impact via Biotech: Leadership during the COVID Pandemic - Organized by Venture Center and ABLE –	
Objective	<ul style="list-style-type: none"> To provide a platform for Biotech industry and researchers to network To acknowledge the efforts of BioPharma and Biotech organizations during COVID pandemic To announce the association of ABLE and Venture Center
ORGANIZED BY	<ul style="list-style-type: none"> Venture Center, Pune and ABLE India
SUPPORTED BY	<ul style="list-style-type: none"> BIRAC BioNEST at Venture Center — West Zone Chapter of ABLE India at Venture Center
FOR WHOM	<ul style="list-style-type: none"> Startups, Researchers, Indian companies, and multinationals
WHEN	Friday, 15 July 2022 Time: 04:00 pm – 6:00 pm
WHERE	<ul style="list-style-type: none"> This Event will be available to attend Online (Zoom) & Offline (Venture Center) Link to the Event & Details will be shared with selected participants. Venue: Lecture Theater (900 NIP, Venture Center) Kindly Choose option as suitable in registration form Confirmation email will be shared with participants for the event
CONTACT	<p>Technical queries: Meghana Bhandari Email: meghana.bhandari@venturecenter.co.in</p> <p>Registration queries: Lipika Biswas Email: eventsdesk@venturecenter.co.in</p>
REGISTRATION	<p>Registration is free but Mandatory</p> <p>Steps for registration:</p> <ul style="list-style-type: none"> Step 1: Interested participants need to fill in registration form at the following link. Register online at: https://forms.gle/WCqvXhaTAzYR1j4y7 Step 2: Online and Offline Attendance only on confirmation from organizers. <p>Note: -</p> <ul style="list-style-type: none"> Organizers reserve the right to select participants to maximize learning and networking opportunities for the group Session will be conducted using ZOOM online & offline. Only registered participants will be allowed to participate in the event.

Introduction

Bio Pune Seminar Series presents talks in the area of Bio Technology, Biomedical Engineering, Bioinformatics, Biomass value addition and related areas which are of interest and relevance to the bio sciences based technology and entrepreneurship community in Pune.

Event Highlights:

- Celebration of Biotech Industry Making a Big Difference During COVID 19
- Meet, Greet & Network with the Stars
- Announcement of Venture Center hosting ABLE India's West Zone Chapter
- Recognize Venture Center's Efforts Against COVID
- Celebrate Pune's Biotech Innovation Ecosystem

Venue: Lecture Theater at Venture Center





Time (pm)	Duration	Session Title	Lead
4.00 -4:15	15 min	About the Program and Organizers	Narendra Chirmule (Chief Scientific Officer, Aculmmune. Freelance) Smita Kale (Manager, Bioincubation- Venture Center) G S Krishnan (President, ABLE-India)
4.15- 4.25	10 min	Welcome remarks. Overview of VC efforts for COVID-19	Premnath V (Director, Venture Center)
4.25 - 4.45	20 min	Story of Covishield	Umesh Shaligram (Executive Director, Serum Institute of India)
4.45 -5.05	20 min	How Mylab Innovated for a billion people	Shailendra Kawade (Cofounder & Chairman of Board, MyLab Discovery Solutions)
5.05- 5.25	20 min	Paradigm Shift in Vaccinology: mRNA & CRISPR-Cas9	Sanjay Singh (CEO, Gennova Biopharmaceuticals)
5.25- 5.40	15 min	Closing remarks and Felicitation of Biotech Leaders	Narendra Chirmule ,Premnath V
5.40- 6.00	20 min	Networking & High Tea	-

Speakers (in alphabetical order of last names)



Narendra Chirmule **Chief Scientific Officer, Aculmmune. Freelance**

Narendra Chirmule is a Biotechnology professional and a music enthusiast. He has published and presented seminars on subjects of immunology, biologics and vaccines and contributed to development of vaccines and biologics. The drug development experiences include Vaccines for cervical cancer [HPV], shingles [Varicella zoster], childhood diarrhoea [Rotavirus]), and Biologics for osteoporosis [Prolia], rheumatoid arthritis [Enbrel], platelet loss (NPlate) breast cancer (Ogrivi) among many others. He has worked on basic concepts of gene therapy using viral vectors. He did his PhD on development of a leprosy vaccine, from Cancer Research Institute, Mumbai; post-doctoral studies on pathogenesis of AIDS from Cornell University Medical College-North Shore Hospital, and taught immunology at the University of Pennsylvania.

	<p>Shailendra Kawade Co-founder and Chairman of the Board of Mylab Discovery Solutions</p> <p>Mr. Shailendra Kawade is the Co-founder and Chairman of the Board of Mylab Discovery Solutions. He co-founded Mylab and is instrumental in setting the vision for the company. With more than 15 years of experience in the life science industry, Mr. Kawade has a deep understanding of changing techno-commercial dynamics of life science, diagnostic and pharma industry.</p>
	<p>G S Krishnan President, ABLE-India</p> <p>Mr. Krishnan is an experienced thought-leader in the Industrial Bio-tech Segment propagating Sustainable solutions across the SAARC countries with Global market exposure. He has in-depth knowledge and vast experience in overall Strategy and General Management capabilities in a multinational environment, with a total tenure spanning more than 35 years. After a 27 year tenure at a Danish Biotech company, Novozymes South Asia Pvt. Ltd, majority of the role as Managing Director and Regional President, is now engaged as Independent Director, Advisor/Consultant, and Leadership Mentor across the Industrial segments. He is looking forward to supporting the Biotech sector at large and the startups in particular to address the future challenges with innovative ideas and envisioning India to become a booming Bio economy and lead the world.</p>
	<p>Umesh Shaligram Executive Director, Serum Institute of India</p> <p>Umesh Shaligram (Ph.D.), Executive Director of Board of Serum Institute of India, leads the manufacturing of COVISHIELD and COVOVAX Covid-19 vaccines. He also leads research, development and manufacturing of several products at SIPL. These products are recombinant vaccines, proteins, polysaccharides and also newer technologies like polysialylation, biosimilars and biobetters. He is also spearheading SIPL's strategies for (i) TB eradication with novel products based on detection, treatment and prevention (ii) HIV prevention and therapy (iii) Malaria Vaccine (iv) Pertussis vaccine and (v) HPV Vaccine. He has experience of various technologies involved in the field of biologics, biosimilars, biobetters and has led several collaborations, tech-transfers and business relations with various companies and research organizations. He has also actively involved in regulatory interaction with several regulatory agencies in the world.</p>
	<p>Sanjay Singh CEO, Gennova Biopharmaceuticals Ltd.</p> <p>Dr. Sanjay Singh is the Chief Executive Officer of Gennova Biopharmaceuticals Ltd, Pune, India, a biotechnology company dedicated to the development and commercialization of safe, efficacious, and affordable bio-therapeutics. As a founder CEO, since 2006, at Gennova, Dr. Singh has focused on innovations in bio-manufacturing technologies that culminated in the commercialization of seven life-saving biotherapeutics in the cardiovascular, neurology, nephrology, and oncology market. His scientific background has enabled and fostered a research environment. Dr. Singh has actively mentored three Ph.D candidates and several research projects. Dr. Singh has led Gennova to develop India's first mRNA-based vaccine, which got the Emergency Use Authorization (EUA) from the CDSCO and will be available in the market for adults above 18 years of age under the brand name "GEMCOVAC™-19". This is the first thermostable mRNA-based vaccine in the world that can be stored at 2 – 8° C, not requiring ultra-lowtemperature conditions for storage and handling. Also, this research endeavor was recognized by the ET India Pharmaworld Awards and he has been conferred the Researcher of the Year 2022. Under his leadership, his team pioneered the work that led to the approval of tenecteplase for Acute Ischemic Stroke (AIS) – the first time globally, securing global patents. The Department of Biotechnology (DBT), Govt. of India recognized this innovation for the 'Biotech product, process development and commercialization award 2019' and it found its way in the list of drugs for emergency care for stroke management in the guideline – 'Prevention and Management of Stroke,' issued by the Ministry of Health and Family Welfare, Govt. of India. . He is currently a member of the various important committee of national relevance Dr. Singh holds a Ph.D. degree in Biochemistry from Central Drug Research Institute (CDRI), Lucknow, India. Before joining Gennova, he headed the Antigen Research Section at the Malaria Vaccine Development Unit of the National Institutes of Allergy and Infectious Diseases (NIAID), NIH, USA.</p>

Organizers (in alphabetical order of last names)	
	<p>Meghana Bhandari Associate- Bioincubation, Venture Center</p> <p>Meghana is responsible for planning & co-coordinating activities of BRBC. She studied M.Tech in Biomedical engineering from IIT Ropar. During her Masters she did her project work on intranasal drug delivery system for treating Alzheimer's Disease. Previously she has worked as a medical writer for a biopharma company.</p>
	<p>Smita Kale Manager –Bioincubation, Venture Center</p> <p>Smita as part of incubation team, facilitates incubator operations by interacting with incubatees, infrastructure and facilities creation and development of the ecosystem. She is leading Bio-incubation activities, Center for Biopharma Analysis (CBA) and BIRAC's Regional Bioinnovation Center (BRBC) projects at Venture Center. She is actively involved in mentoring startups at Venture Center. She is Ph. D in Pharmaceutical Chemistry from Institute of Chemical Technology, Mumbai and prior to joining Venture Center has had academic experience of 12 years which includes research experience of 3.6 years.</p>
	<p>Premnath V Director, Venture Center Head, NCL Innovations</p> <p>Premnath V is currently the Head, National Chemical Laboratory (NCL) Innovations - the group within NCL charged with the responsibility of championing the cause of technology innovation within NCL. Dr Premnath is also the Founding Director of the Venture Center - a technology business incubator on NCL campus. Dr Premnath is also a Scientist, Polymer Science & Engineering Division at NCL with an interest in technology development for biomedical products. He holds a B. Tech. from the Indian Institute of Technology - Bombay and a Ph.D. from the Massachusetts Institute of Technology, USA. He has also been a Chevening Technology Enterprise Fellow with the Centre for Scientific Enterprises, London Business School and Cambridge University, UK. He brings with him considerable experience in technology development and commercialization (two successfully commercialized families of products), working with start-up companies (in Cambridge-UK and India) and engaging with large corporations on research and consulting projects as project leader.</p>
Organized by	
	<p>Entrepreneurship Development Center (Venture Center) – a CSIR initiative – is a Section 25 company hosted by the National Chemical Laboratory, Pune. Venture Center strives to nucleate and nurture technology and knowledge-based enterprises by leveraging the scientific and engineering competencies of the institutions in the Pune region in India. The Venture Center is a technology business incubator supported by the Department of Science & Technology's National Science & Technology Entrepreneurship Development Board (DST-NSTEDB). Venture Center's focuses on technology enterprises offering products and services exploiting scientific expertise in the areas of materials, chemicals and biological sciences & engineering.</p> <p>For more information, visit: http://www.venturecenter.co.in/</p>
	<p>Association of Biotechnology Led Enterprises – ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector.</p> <p>ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Biopharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital Firms and Equipment Suppliers. The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector.</p> <p>For more information, visit: https://ableindia.in/</p>